BackChina NT Pharma Group Company Limited Overview

China NT Pharma Group Company Limited Inventory

Latest inventory for 1011.HK: $2.1M.

Get informed when a big investor buys or sells

+ Follow
Inventory
$2.05M
↑ 357.60% YoYΔ $1.61M vs prior year quarter

Peer trimmed avg / median

Loading

China NT Pharma Group Company Limited Inventory History

Loading

China NT Pharma Group Company Limited vs. peers: Inventory Comparison

Loading

China NT Pharma Group Company Limited Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

China NT Pharma Group Company Limited (1011.HK) FAQ

China NT Pharma Group Company Limited posts a inventory of $2.1M as of June 2026. That compares with $450K in the prior-year period — up 357.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, China NT Pharma Group Company Limited's inventory was $450K. The latest reading is $2.1M — a 357.6% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Inventory is one piece of China NT Pharma Group Company Limited's financial statement story. At $2.1M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 1011.HK's inventory usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; China NT Pharma Group Company Limited's other metric pages and overview cover the third.

Judging China NT Pharma Group Company Limited against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in inventory easier to interpret. Start with $2.1M here, then scan peer and history charts to see if the gap is persistent.